search
close_mark

Julianna Pherarolis

Julianna Pherarolis

25 Jun, 2025

“I am incredibly satisfied with the work Celegence has done thus far. They communicate well and receive feedback well. I find the team I have been assigned incredibly easy to work with, friendly, and people I genuinely look forward to speaking with once a week.”

Dr. Carlos Munoz-Viveros
Read Now

Other Related Articles

Heavy Metals in Pharmaceuticals: A Critical Quality and Safety Imperative
Blog Pharmaceutical

Heavy Metals in Pharmaceuticals: A Critical Quality and Safety Imperative

10 Apr, 2026

EMA Roadmap Update: PMS Capabilities and the End of the Legacy Era
Blog Pharmaceutical

EMA Roadmap Update: PMS Capabilities and the End of the Legacy Era

01 Apr, 2026

Expanded Access Approval : Balancing Urgency and Oversight in Regulatory Affairs
Blog Pharmaceutical

Expanded Access Approval : Balancing Urgency and Oversight in Regulatory Affairs

26 Mar, 2026

How to Reduce Notified Body Review Cycles Through Better Clinical Documentation
Blog Medical Devices

How to Reduce Notified Body Review Cycles Through Better Clinical Documentation

18 Mar, 2026

The Great Convergence — Why 2026 is the Year Regulatory “Records” Die
Blog Pharmaceutical

The Great Convergence — Why 2026 is the Year Regulatory “Records” Die

10 Mar, 2026

Raw Material Compliance in Pharmaceuticals: Naming, Pharmacopeial Grade, and Safety Requirements
Blog Pharmaceutical

Raw Material Compliance in Pharmaceuticals: Naming, Pharmacopeial Grade, and Safety Requirements

24 Feb, 2026

EMA Upgrades xEVMPD Web Interface
Blog Pharmaceutical

EMA Upgrades xEVMPD Web Interface

19 Feb, 2026

Raw Material Compliance in Pharmaceuticals
Blog Pharmaceutical

Raw Material Compliance in Pharmaceuticals

13 Feb, 2026

View All